Study Evaluating Combination of Levonorgestrel and Ethinyl Estradiol in Pre-Menstrual Dysphoric Disorder

NCT ID: NCT00195559

Last Updated: 2007-12-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

526 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-09-30

Study Completion Date

2007-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether Levonorgestrel/Ethinyl Estradiol (LNG/EE) is effective in treating the symptoms of severe Premenstrual Dysphoric Disorder.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Premenstrual Syndrome Menstruation Disturbances

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Premenstrual Syndrome (PMS) Hormone Therapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Levonorgestrel/Ethinyl Estradiol

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Generally healthy, women aged 18 to 49 years.
* History of severe PMS symptoms over the last year, as determined by the investigator.
* Regular 21 to 35 day menstrual cycle for 2 months prior to first study visit.

Exclusion Criteria

* Major depressive disorder requiring antidepressant treatment or hospitalization within the last 3 years.
* Contraindication to combination oral contraceptives.
* Use of antidepressants/anxiolytics within 10 days of screening and for the duration of the study.

Other exclusion applies.
Minimum Eligible Age

18 Years

Maximum Eligible Age

49 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Argentina, Chile, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Brazil, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Denmark, Finland, Sweden, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Germany, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Mexico, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Netherlands, [email protected]

Trial Managersp

Role: PRINCIPAL_INVESTIGATOR

For Poland, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Romania, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For UK, [email protected]

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Buenos Aires, , Argentina

Site Status

Córdoba, , Argentina

Site Status

Rosario-Santa Fe, , Argentina

Site Status

Curitiba, , Brazil

Site Status

Goiânia, , Brazil

Site Status

Porto Alegre, , Brazil

Site Status

Salvador, , Brazil

Site Status

São Paulo, , Brazil

Site Status

Sorocaba, , Brazil

Site Status

Santiago, , Chile

Site Status

Temuco, , Chile

Site Status

Aarhus, , Denmark

Site Status

Frederiksberg, , Denmark

Site Status

København NV, , Denmark

Site Status

Rungsted Kyst, , Denmark

Site Status

Helsinki, , Finland

Site Status

Kuopio, , Finland

Site Status

Oulu, , Finland

Site Status

Turku, , Finland

Site Status

Berlin, , Germany

Site Status

Bonn, , Germany

Site Status

Hamburg, , Germany

Site Status

Hanover, , Germany

Site Status

Lomas de Virreyes, D.F., Mexico

Site Status

Guadalajara, Jalisco, Mexico

Site Status

Zapopan, Jalisco, Mexico

Site Status

Monterrey, N.L., Mexico

Site Status

San Luis Potosí City, San Luis Potosí, Mexico

Site Status

Mexico City, , Mexico

Site Status

Amsterdam, , Netherlands

Site Status

Apeldoorn, , Netherlands

Site Status

Den Helder, , Netherlands

Site Status

Enschede, , Netherlands

Site Status

Nieuwegein, , Netherlands

Site Status

Bialystok, , Poland

Site Status

Gdansk, , Poland

Site Status

Mysłowice, , Poland

Site Status

Poznan, , Poland

Site Status

Warsaw, , Poland

Site Status

S

Bucharest, , Romania

Site Status

Cluj-Napoca, , Romania

Site Status

Iași, , Romania

Site Status

Gothenburg, , Sweden

Site Status

Stockholm, , Sweden

Site Status

Umeå, , Sweden

Site Status

Uppsala, , Sweden

Site Status

Conwell, , United Kingdom

Site Status

Fowey, , United Kingdom

Site Status

London, , United Kingdom

Site Status

Plymouth, , United Kingdom

Site Status

St Austell, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Argentina Brazil Chile Denmark Finland Germany Mexico Netherlands Poland Romania Sweden United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0858A4-318

Identifier Type: -

Identifier Source: org_study_id